nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

27.11.2017 | Original Article

A first-in-man PET study of [¹⁸F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5

verfasst von: Geoffrey Warnock, Michael Sommerauer, Linjing Mu, Gloria Pla Gonzalez, Susanne Geistlich, Valerie Treyer, Roger Schibli, Alfred Buck, Stefanie D. Krämer, Simon M. Ametamey

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Non-invasive imaging of metabotropic glutamate receptor 5 (mGlu₅) in the brain using PET is of interest in e.g., anxiety, depression, and Parkinson’s disease. Widespread application of the most widely used mGlu₅ tracer, [¹¹C]ABP688, is limited by the short physical half-life of carbon-11. [¹⁸F]PSS232 is a fluorinated analog with promising preclinical properties and high selectivity and specificity for mGlu₅. In this first-in-man study, we evaluated the brain uptake pattern and kinetics of [¹⁸F]PSS232 in healthy volunteers.

Methods

[¹⁸F]PSS232 PET was performed with ten healthy male volunteers aged 20–40 years. Seven of the subjects received a bolus injection and the remainder a bolus/infusion protocol. Cerebral blood flow was determined in seven subjects using [¹⁵O]water PET. Arterial blood activity was measured using an online blood counter. Tracer kinetics were evaluated by compartment modeling and parametric maps were generated for both tracers.

Results

At 90 min post-injection, 59.2 ± 11.1% of total radioactivity in plasma corresponded to intact tracer. The regional first pass extraction fraction of [¹⁸F]PSS232 ranged from 0.41 ± 0.06 to 0.55 ± 0.03 and brain distribution pattern matched that of [¹¹C]ABP688. Uptake kinetics followed a simple two-tissue compartment model. The volume of distribution of total tracer (V _T, ml/cm³) ranged from 1.18 ± 0.20 for white matter to 2.91 ± 0.51 for putamen. The respective mean distribution volume ratios (DVR) with cerebellum as the reference tissue were 0.88 ± 0.06 and 2.12 ± 0.10, respectively. The tissue/cerebellum ratios of a bolus/infusion protocol (30/70 dose ratio) were close to the DVR values.

Conclusions

Brain uptake of [¹⁸F]PSS232 matched the distribution of mGlu₅ and followed a two-tissue compartment model. The well-defined kinetics and the possibility to use reference tissue models, obviating the need for arterial blood sampling, make [¹⁸F]PSS232 a promising fluorine-18 labeled radioligand for measuring mGlu₅ density in humans.

Nur mit Berechtigung zugänglich

Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol. 2004;19:343–360; discussion 61. https://doi.org/10.1177/088307380401900507.CrossRefPubMed

Gereau RW, Conn PJ. Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. J Neurophysiol. 1995;74:122–9.CrossRefPubMed

Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J Neurosci. 2000;20:3085–94.CrossRefPubMed

Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol. 2005;97:202–13. https://doi.org/10.1111/j.1742-7843.2005.pto_156.x.CrossRefPubMed

Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267–75.PubMed

Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–30. https://doi.org/10.1038/sj.bjp.0703923.CrossRefPubMedPubMedCentral

Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res. 1998;56:207–17.CrossRefPubMed

Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther. 2000;88:427–35.CrossRefPubMed

Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4:873–4. https://doi.org/10.1038/nn0901-873.CrossRefPubMed

10.

Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001;40:1–9.CrossRefPubMed

11.

Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology. 2001;40:10–9.CrossRefPubMed

12.

Sotgiu ML, Bellomi P, Biella GE. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci Lett. 2003;342:85–8.CrossRefPubMed

13.

Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med. 2006;47:698–705.PubMed

14.

Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med. 2007;48:247–52.PubMed

15.

Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry. 2013;73:161–8. https://doi.org/10.1016/j.biopsych.2012.07.030.CrossRefPubMed

16.

Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci U S A. 2013;110:737–42. https://doi.org/10.1073/pnas.1210984110.CrossRefPubMed

17.

Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, et al. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol Psychiatry. 2014;19:625–32. https://doi.org/10.1038/mp.2013.51.CrossRefPubMed

18.

DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo ketamine-induced changes in [(1)(1)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry. 2015;77:266–75. https://doi.org/10.1016/j.biopsych.2014.06.024.CrossRefPubMed

19.

Milella MS, Marengo L, Larcher K, Fotros A, Dagher A, Rosa-Neto P, et al. Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. NeuroImage. 2014;98:195–202. https://doi.org/10.1016/j.neuroimage.2014.04.061.CrossRefPubMed

20.

Brown AK, Kimura Y, Zoghbi SS, Simeon FG, Liow JS, Kreisl WC, et al. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med. 2008;49:2042–8. https://doi.org/10.2967/jnumed.108.056291.CrossRefPubMedPubMedCentral

21.

Sullivan JM, Lim K, Labaree D, Lin SF, McCarthy TJ, Seibyl JP, et al. Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J Cereb Blood Flow Metab. 2013;33:532–41. https://doi.org/10.1038/jcbfm.2012.195.CrossRefPubMed

22.

Leurquin-Sterk G, Postnov A, de Laat B, Casteels C, Celen S, Crunelle CL, et al. Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer 18F-FPEB in human brain. Synapse. 2016;70:153–62. https://doi.org/10.1002/syn.21890.CrossRefPubMed

23.

Stephenson NA, Holland JP, Kassenbrock A, Yokell DL, Livni E, Liang SH, et al. Iodonium ylide-mediated radiofluorination of 18F-FPEB and validation for human use. J Nucl Med. 2015;56:489–92. https://doi.org/10.2967/jnumed.114.151332.CrossRefPubMedPubMedCentral

24.

Milicevic Sephton S, Mu L, Dragic M, Müller A, Krämer SD, Schibli R, et al. Synthesis and in vitro evaluation of E and Z isomers of PSS232 as potential mGluR5 binders. Synthesis. 2013;45:1877–85.CrossRef

25.

Milicevic Sephton S, Herde Müller A, Mu L, Keller C, Rüdisühli S, Auberson Y, et al. Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). Eur J Nucl Med Mol Imaging. 2015;42:128–37. https://doi.org/10.1007/s00259-014-2883-7.CrossRef

26.

Müller Herde A, Keller C, Milicevic Sephton S, Mu L, Schibli R, Ametamey SM, et al. Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity. J Neurochem. 2015;133:330–42. https://doi.org/10.1111/jnc.13001.CrossRefPubMed

27.

Meyer E. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. J Nucl Med. 1989;30:1069–78.PubMed

28.

Krämer SD, Betzel T, Mu L, Haider A, Herde Müller A, Boninsegni AK, et al. Evaluation of 11C-Me-NB1 as a potential PET radioligand for measuring GluN2B-containing NMDA receptors, drug occupancy and receptor crosstalk. J Nucl Med. in press.

29.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533. https://doi.org/10.1038/sj.jcbfm.9600493.CrossRefPubMed

30.

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time–activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7. https://doi.org/10.1038/jcbfm.1990.127.CrossRefPubMed

31.

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–40. https://doi.org/10.1097/00004647-199609000-00008.CrossRefPubMed

32.

Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;AC-19:716–23.CrossRef

33.

Hurvich CM, Tsai C-L. Regression and time series model selection in small samples. Biometrika. 1989;76:297–307.CrossRef

34.

Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med. 2007;48:1207–15. https://doi.org/10.2967/jnumed.107.039578.CrossRefPubMed

35.

Krämer SD. Quantitative aspects of drug permeation across in vitro and in vivo barriers. Eur J Pharm Sci. 2016;87:30–46. https://doi.org/10.1016/j.ejps.2015.10.013.CrossRefPubMed

36.

Wang JQ, Tueckmantel W, Zhu A, Pellegrino D, Brownell AL. Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse. 2007;61:951–61. https://doi.org/10.1002/syn.20445.CrossRefPubMed

37.

Pillai RL, Tipre DN. Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging. Eur J Nucl Med Mol Imaging. 2016;43:1151–70. https://doi.org/10.1007/s00259-015-3301-5.CrossRefPubMed

38.

Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. mRNA and protein expression for novel GABAA receptors theta and rho2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry. 2013;3:e271. https://doi.org/10.1038/tp.2013.46.CrossRefPubMedPubMedCentral

39.

Gulyas B, Sovago J, Gomez-Mancilla B, Jia Z, Szigeti C, Gulya K, et al. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain. Brain Struct Funct. 2015;220:3043–51. https://doi.org/10.1007/s00429-014-0812-y.CrossRefPubMed

40.

Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol. 2007;34:1009–17. https://doi.org/10.1016/j.nucmedbio.2007.07.009.CrossRefPubMed

41.

Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46–50. https://doi.org/10.1038/jcbfm.2009.190.CrossRefPubMed

42.

Burger C, Deschwanden A, Ametamey S, Johayem A, Mancosu B, Wyss M, et al. Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl Med Biol. 2010;37:845–51. https://doi.org/10.1016/j.nucmedbio.2010.04.107.CrossRefPubMed

43.

Rostomian, A.H., Madison, C., Rabinovici, G.D., Jagust, W.J., 2011. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 52:173–179

44.

Ing-Tsung Hsiao, Chin-Chang Huang, Chia-Ju Hsieh, Shiaw-Pyng Wey, Mei-Ping Kung, Tzu-Chen Yen, Kun-Ju Lin, (2013) Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. European Journal of Nuclear Medicine and Molecular Imaging 40 (6):908–920

Titel: A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5
verfasst von: Geoffrey Warnock
Michael Sommerauer
Linjing Mu
Gloria Pla Gonzalez
Susanne Geistlich
Valerie Treyer
Roger Schibli
Alfred Buck
Stefanie D. Krämer
Simon M. Ametamey
Publikationsdatum: 27.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3879-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment

Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI

The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma

11C–acetate PET/CT: a potential alternative of transcranial biopsy for grading cerebral gliomas

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index